Abstract
Background/Aims: Viral infections are a major problem worldwide and many of them are complicated by virally induced glomerulonephritides. Progression of kidney disease to renal failure is mainly attributed to the development of renal fibrosis characterized by the accumulation of extracellular matrix components in the mesangial cell compartment and the glomerular basement membrane. Plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator (t-PA) are major regulators of plasmin generation and play an important role in generation and degradation of glomerular extracellular matrix components. Viral receptors expressed by mesangial cells (MC) are known to be key mediators in immune-mediated glomerulonephritis. We investigated the effect of stimulation of the viral receptors toll-like receptor 3 (TLR3) and retinoic acid-inducible gene I (RIG-I) on the expression of PAI-1 and t-PA. Methods: Expression of PAI-1 and t-PA in immortalized human MC stimulated with polyriboinosinic:polyribocytidylic acid [poly(I:C)] RNA and cytokines were analyzed by real-time RT-PCR and ELISA. Results: Incubation of MC with poly(I:C) RNA to activate the viral receptors TLR3 and RIG-I upregulates the expression of PAI-1 and t-PA. Knockdown of viral receptors with specific siRNA abolishes the induction of PAI-1 and t-PA. Conclusion: For the first time a link between the activation of viral receptors on MC and potentially causative agents in the development of glomerulosclerosis and tubulointerstitial fibrosis is shown. The progression of inflammatory processes to glomerulosclerosis can be postulated to be directly enhanced by viral infection.
References
1.
Baricos WH, Cortez SL, el-Dahr SS, et al: ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 1995;47:c1039–c1047.
[PubMed]
2.
Vassalli JD, Sappino AP, Belin D: The plasminogen activator/plasmin system. J Clin Invest 1991;88:c1067–c1072.
[PubMed]
3.
Kincaid-Smith P: Coagulation and renal disease. Kidney Int 1972;2:c183–c190.
[PubMed]
4.
Nield GH, Cameron JS: Primary glomerulonephritis; in Remuzzi G, Rossi EC (eds): Haemostasis and the Kidney. London, Butterworth, 1989, pp 56–64.
5.
Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992;20:c1–c17.
[PubMed]
6.
Floege J, Gröne HJ: Progression of renal failure: what is the role of cytokines? Nephrol Dial Transplant 1995;10:c1575–c1586.
[PubMed]
7.
Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 1988;318:c1657–c1666.
[PubMed]
8.
Grandaliano G, Gesualdo L, Ranieri E, et al: Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis. Am J Kidney Dis 2000;35:c726–c738.
[PubMed]
9.
Hamano K, Iwano M, Akai Y, et al: Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis 2002;39:c695–c705.
[PubMed]
10.
Purkerson ML, Joist JH, Greenberg JM, et al: Inhibition by anticoagulant drugs of the progressive hypertension and uremia associated with renal infarction in rats. Thromb Res 1982;26:c227–c240.
[PubMed]
11.
Rondeau E, Mougenot B, Lacave R, et al: Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. Clin Nephrol 1990;33:c55–c60.
[PubMed]
12.
Agnello V, Chung RT, Kaplan LM: A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992,327:c1490–c1495.
[PubMed]
13.
Meyers CM, Seef LB, Stehman-Breen CO, Hoofnagle JH: Hepatitis C and renal disease: an update. Am J Kidney Dis 2003,42:c631–c657.
[PubMed]
14.
Klotman PE: HIV-associated nephropathy. Kidney Int 1999,56:c1161–c1176.
[PubMed]
15.
D’Amico G: The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987;64:c709–c727.
[PubMed]
16.
Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:c675–c680.
[PubMed]
17.
Anders HJ, Banas B, Schlöndorff D: Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 2004;15:c854–c867.
[PubMed]
18.
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature 2001;413:c732–c738.
[PubMed]
19.
Matsumoto M, Kikkawa S, Kohase M, et al: Establishment of a monoclonal antibody against human toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun 2002;293:c1364–c1369.
[PubMed]
20.
Cario E, Podolsky DK: Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:c7010–c7017.
[PubMed]
21.
Vitour D, Meurs EF: Regulation of interferon production by RIG-I and LGP2: a lesson in self-control. Sci STKE 2007;384:c20.
22.
Uchiyama-Tanaka Y, Mori Y, Kishimoto N, et al: Membranous glomerulonephritis associated with hepatitis C virus infection: case report and literature review. Clin Nephrol 2004;61:c144–c150.
[PubMed]
23.
Wörnle M, Schmid H, Banas B, et al: Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol 2006;168:c370–c385.
[PubMed]
24.
Wörnle M, Roeder M, Sauter M, Ribeiro A: Role of matrix metalloproteinases in viral-associated glomerulonephritis. Nephrol Dial Transplant 2009;24:1113–1121.
[PubMed]
25.
Banas B, Luckow B, Moller M, et al: Chemokine and chemokine receptor expression in a novel human mesangial cell line. J Am Soc Nephrol 1999,10:c2314–c2322.
[PubMed]
26.
Porubsky S, Schmid H, Bonrouhi M, et al: Influence of native and hypochlorite-modified low-density lipoprotein on gene expression in human proximal tubular epithelium. Am J Pathol 2004,164:c2175–c2187.
[PubMed]
27.
Matsukura S, Kokubu F, Kurokawa M, et al: Role of RIG-I, MDA-5, and PKR on the expression of inflammatory chemokines induced by synthetic dsRNA in airway epithelial cells. Int Arch Allergy Immunol 2007;143(suppl 1):c80–c83.
[PubMed]
28.
Keeton M, Ahn C, Eguchi Y, et al: Expression of type I plasminogen activator inhibitor in renal tissue in murine lupus nephritis. Kidney Int 1995;47:c148–c157.
[PubMed]
29.
Patole P, Gröne HJ, Segerer S, et al: Viral double-stranded RNA aggravates lupus nephritis through toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005;16:c1326–c1338.
[PubMed]
30.
Matsumoto M, Funami K, Tanabe M, et al: Subcellular localization of toll-like receptor 3 in human dendritic cells. J Immunol 2003;171:c3154–c3162.
[PubMed]
31.
Marshall-Clarke S, Downes JE, Haga IR, et al: Polyinosinic acid is a ligand for toll-like receptor 3. J Biol Chem 2007;282:c24759–c24766.
[PubMed]
32.
Aya N, Yoshioka K, Murakami K, et al: Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis. J Pathol 1992;166:c289–c295.
[PubMed]
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.
